Leukemia Patients Remain in Remission More Than Two Years After Engineered T Cell Therapy
Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania. Penn Medicine researchers are to present the latest results of the trial December 10 at the American Society of Hematology's Annual Meeting and Exposition. Read more: http://bit.ly/XJLxc8
(https://fbcdn-sphotos-f-a.akamaihd.net/hphotos-ak-prn1/p480x480/297853_133076623514740_1926960570_n.jpg)
Image: Colored SEM of a T Lymphocyte Credit: David Scharf, Science Photo Library